DSMB supports continuation of Anthera Phase 2 impacts trial for the prevention of acute chest syndrome in patients with sickle cell disease

News | 04. 16. 2008

Anthera Pharmaceuticals

SAN MATEO, CA – April 16, 2008 – Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that after completing its review of safety and efficacy data currently available, an independent Data Safety Monitoring Board (DSMB) has recommended that Anthera’s Phase II clinical trial, known as the IMPACTS (Investigation of the Modulation of Phospholipase in Acute ChesT Syndrome) Study can continue under the current protocol, without change.